法尼甾体X受体
脂肪肝
医学
中医药
疾病
机制(生物学)
药物开发
药品
酒精性肝病
内科学
药理学
生物信息学
核受体
替代医学
生物
病理
基因
生物化学
转录因子
肝硬化
认识论
哲学
作者
Huanhuan Zhao,Ji Cui,Jinjia Zhang,Jiaxin Chen,Anhua Shi,Xiaosong Zhu
出处
期刊:PubMed
[National Institutes of Health]
日期:2023-12-01
卷期号:48 (24): 6582-6591
标识
DOI:10.19540/j.cnki.cjcmm.20230809.701
摘要
Non-alcoholic fatty liver disease(NAFLD) is a chronic metabolic condition with rapidly increasing incidence, becoming a public health issue of worldwide concern. Studies have shown that farnesoid X receptor(FXR)-based modulation of downstream targets can improve liver function and metabolic status in the patients with NAFLD and may be a potential drug target for treating this di-sease. Great progress has been achieved in the development of drugs targeting FXR for the treatment of NAFLD. A number of studies have explored the traditional Chinese medicine and their active ingredients for the treatment of NAFLD via FXR considering the high safety and efficacy and mild side effects. This paper systematically describes the mechanism of traditional Chinese medicines in the treatment of NAFLD via FXR and the downstream targets, aiming to provide precise targets for the drug development and clinical treatment of NAFLD.
科研通智能强力驱动
Strongly Powered by AbleSci AI